European decision could give longer patent protection worth €billions to companies
This article was originally published in Scrip
Executive Summary
Companies operating in Europe could stand to dramatically increase their revenues if the Court of Justice of the European Union (CJEU) upholds yesterday's opinion from one of its advocate generals, Yves Bot, on allowing negative term supplementary protection certificates (SPCs). A green light for such SPCs would pave the way for companies to benefit from longer patent protection in every EU country.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.